Kalpana Kalpana

Emicizumab

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
Type  Whole antibody
Routes of administration  Subcutaneous injection
Legal status  Investigational
Source  Humanized
ATC code  None
Emicizumab 182922305082drugbiologyPB0288AEC910struct
Target  Activated factor IX, factor X

Emicizumab (ACE910) is an investigational monoclonal antibody for the treatment of haemophilia A, being developed by Chugai. A Phase I clinical trial found that it was well tolerated by healthy subjects.

Mechanism of action

Emicizumab binds to both the activated coagulation factor IX and to factor X, mediating the activation of the latter. This is normally the function of coagulation factor VIII, which is missing in haemophilia A patients.

References

Emicizumab Wikipedia


Similar Topics
A Bone for a Bone
Michael Aram
Carlos Septien
Topics